Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from the Phase III persevERA Breast Cancer study evaluating investigational giredestrant in combination ...

The study did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a ...

Allarity closes $20 mn financing to accelerate the advance of stenoparib toward US FDA approval and commercialization: Tarpon Springs, Florida Monday, March 9, 2026, 15:00 Hrs [IS ...

ERA Breast Cancer study did not meet the primary objective of a statistically significant improvement in progression-free survival, but a numerical improvement was observed Giredestrant plus palbocicl ...

Cardiol Therapeutics (NASDAQ:CRDL) used a presentation at TD Cowen’s 46th Annual Healthcare Conference to outline its clinical development programs targeting inflammation in cardiac disease, with its ...

The global natural sweeteners market has been expanding at a steady pace. According to multiple industry analyses, the market was valued at approximately $2.8 billion recently and is projected to grow ...